Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
Pegargiminase-pemetrexed-platinum triplet therapy prolongs survival in non-epithelioid pleural mesothelioma
Breast and emerging indications for IORT
The advantages of IORT for early breast cancer treatment
CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC
Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours
VT3989 is safe and well tolerated in patients with advanced malignant mesothelioma and NF2m cancers
Choosing Wisely in medical oncology
Why tumour markers are NOT recommended as screening tests
Hemopathy burden at National Cancer Center
To avoid unnecessary second surgery in differentiated thyroid cancer
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours